JAK2 and myeloid sarcoma: Furthermore, the three prioritized variants identified in this study—RTN4 p.Pro148Leu, JAK2 p.Phe560Val, and DUOX2 p.Tyr1150Cys—highlight distinct yet potentially convergent therapeutic avenues in MS.